Middle East & Africa Human Vaccine Adjuvants Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Middle East & Africa Human Vaccine Adjuvants Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Middle East & Africa Human Vaccine Adjuvants Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Middle East & Africa Human Vaccine Adjuvants Market Regional Analysis

6.2 Middle East & Africa Human Vaccine Adjuvants Market Revenue 2020-2030 (US$ Million)

6.3 Middle East & Africa Human Vaccine Adjuvants Market Forecast Analysis

7. Middle East & Africa Human Vaccine Adjuvants Market Analysis – by Type

7.1 Particulate Adjuvant

7.1.1 Overview
7.1.2 Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.2 Emulsion Adjuvant

7.2.1 Overview
7.2.2 Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.3 Combination Adjuvant

7.3.1 Overview
7.3.2 Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

8. Middle East & Africa Human Vaccine Adjuvants Market Analysis – by Application

8.1 Influenza

8.1.1 Overview
8.1.2 Influenza: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.2 Hepatitis

8.2.1 Overview
8.2.2 Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.3 Human papilloma virus

8.3.1 Overview
8.3.2 Human papilloma virus: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

9. Middle East & Africa Human Vaccine Adjuvants Market Analysis – by End User

9.1 Pharmaceutical and Biotechnology Companies

9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

9.2 CMOs and CROs

9.2.1 Overview
9.2.2 CMOs and CROs: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast, 2020-2030 (US$ Million)

10. Middle East & Africa Human Vaccine Adjuvants Market – Middle East and Africa Analysis

10.1 Overview

10.2 Middle East and Africa

10.2.1 Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Country, 2023 and 2030 (%)
10.2.1.1 Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.2.1.1 South Africa: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.1.1 South Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
10.2.1.1.2 South Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
10.2.1.1.3 South Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User

10.2.1.2 Saudi Arabia: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.2.1 Saudi Arabia: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
10.2.1.2.2 Saudi Arabia: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
10.2.1.2.3 Saudi Arabia: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User

10.2.1.3 UAE: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.3.1 UAE: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
10.2.1.3.2 UAE: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
10.2.1.3.3 UAE: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User

10.2.1.4 Rest of Middle East and Africa: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

10.2.1.4.1 Rest of Middle East and Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
10.2.1.4.2 Rest of Middle East and Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
10.2.1.4.3 Rest of Middle East and Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Novartis AG

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 CSL Ltd

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Seppic SA

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Croda International Plc

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Novavax Inc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Phibro Animal Health Corp

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

Middle East & Africa Human Vaccine Adjuvants Market

Analysis - by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)